BeOne Medicines (NASDAQ:ONC) & ProKidney (NASDAQ:PROK) Head-To-Head Review

BeOne Medicines (NASDAQ:ONC) and ProKidney (NASDAQ:PROK) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their profitability, dividends, institutional ownership, risk, valuation, earnings and analyst recommendations.

Analyst Ratings

This is a breakdown of recent recommendations and price targets for BeOne Medicines and ProKidney, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BeOne Medicines	1	2	11	1	2.80
ProKidney	2	1	4	1	2.50

BeOne Medicines presently has a consensus target price of $389.15, indicating a potential upside of 25.43%. ProKidney has a consensus target price of $7.40, indicating a potential upside of 322.86%. Given ProKidney’s higher probable upside, analysts plainly believe ProKidney is more favorable than BeOne Medicines.

Earnings & Valuation

This table compares BeOne Medicines and ProKidney”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BeOne Medicines	$5.34 billion	6.37	$286.93 million	$4.47	69.41
ProKidney	$890,000.00	593.66	-$68.99 million	($0.53)	-3.30

BeOne Medicines has higher revenue and earnings than ProKidney. ProKidney is trading at a lower price-to-earnings ratio than BeOne Medicines, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares BeOne Medicines and ProKidney’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
BeOne Medicines	8.94%	12.06%	6.69%
ProKidney	-8,131.50%	N/A	-21.39%

Insider & Institutional Ownership

48.6% of BeOne Medicines shares are held by institutional investors. Comparatively, 51.6% of ProKidney shares are held by institutional investors. 6.2% of BeOne Medicines shares are held by company insiders. Comparatively, 39.8% of ProKidney shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Risk & Volatility

BeOne Medicines has a beta of 0.5, suggesting that its stock price is 50% less volatile than the S&P 500. Comparatively, ProKidney has a beta of 1.7, suggesting that its stock price is 70% more volatile than the S&P 500.

Summary

BeOne Medicines beats ProKidney on 9 of the 14 factors compared between the two stocks.

About BeOne Medicines

BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Basel, Switzerland.

About ProKidney

ProKidney Corp., a clinical-stage biotechnology company, provides transformative proprietary cell therapy platform for treating various chronic kidney diseases in the United States. The company's lead product is Renal Autologous Cell Therapy (REACT), an autologous homologous cell admixture, which has completed Phase I clinical trial for REACT in patients with congenital anomalies of the Kidney and Urinary Tract (CAKUT), as well as in Phase III and Phase II clinical trials for the treatment of moderate to severe diabetic kidney disease. ProKidney Corp. founded in 2015 and is headquartered in Winston-Salem, North Carolina.